Hemostemix Grants Stock Options

Core Viewpoint - Hemostemix Inc. has granted a total of 963,000 stock options to its directors, officers, employees, and consultants, subject to regulatory approval, as part of its stock option plan [1][2]. Stock Options Details - Of the 963,000 options granted, 663,000 vest immediately, while 330,000 vest 50% on December 11, 2025, and 50% on December 11, 2026 [2]. - All options have an exercise price of $0.09 per common share and an expiry date of December 11, 2030 [2]. - After this issuance, Hemostemix has a total of 19,124,694 options issued and outstanding [2]. Regulatory Exemptions - Hemostemix relied on section 5.5(b) of Multilateral Instrument 61-101 for exemption from formal valuation requirements, as no securities are listed on a specified market [2]. - The company also utilized section 5.7(a) of MI 61-101 to exempt the minority approval requirements, as the fair market value of the options granted did not exceed 25% of Hemostemix's market capitalization [2]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a Technology Pioneer by the World Economic Forum [3]. - The company has developed and is commercializing its patented blood-based stem cell therapy, VesCell™ (ACP-01), and has completed seven clinical studies involving 318 subjects [3]. - ACP-01 has shown significant clinical relevance and safety in treating various conditions, including peripheral arterial disease and chronic limb threatening ischemia [3]. - The Phase II clinical trial for chronic limb threatening ischemia reported a 0% mortality rate and wound healing in 83% of patients followed for up to 4.5 years [3].